Brenda A. Schulman, PhD, has a longstanding interest in proteostasis. She received her PhD from MIT studying protein folding, before developing an interest in the regulation of protein degradation during her postdoctoral studies at MGH Cancer Center and at Memorial Sloan-Kettering Cancer Center. In 2001, she joined the faculty at St. Jude Children’s Research Hospital where she retains an adjunct faculty position. She was an HHMI Investigator at St. Jude until 2017, when she moved to the Max Planck Institute of Biochemistry as a director.
The Schulman lab defines regulation by ubiquitin and autophagy pathways, especially structural mechanisms underlying these dynamic processes. Dr. Schulman has been recognized by a number of awards including the Leibniz Prize and Ernst Jung Prize in Medicine and is a member of the American Academy of Arts and Sciences, the National Academy of Sciences, EMBO, and Leopoldina.